When: Q3 2026 earnings confirming MLR normalization

Then: Re-evaluate full re-entry thesis

TRIM to 1.5-2% portfolio weight; maintain stop at 355; await clearer fundamental picture before increasing exposure

• Operating margin collapsed from 8.7% in 2023 to 4.2% in 2025, not a one-time event
• Gross margin in 2025 was 18.5%, down from 24.5% in 2023 — medical loss ratio pressure, not cyberattack residual
• OCF declined 32% from 2023 to 2025 — two full years of cash generation erosion
• Change Healthcare cyberattack charge was $8.3 billion in 2024, but 2025 profitability remains below 2023 levels
• Forward EPS recovery estimate of $22.44 (44% recovery) is a Wall Street consensus forecast subject to revision
• Forward P/E of 17.3x is anchored to estimates that may not survive the next earnings cycle
• IRS audit covering four years of taxable income with undisclosed exposure
• Investor lawsuit alleging governance and cybersecurity failures tied to Change Healthcare
• MA membership cuts signal ongoing medical cost trend pressure into 2026
• Lower Bollinger band at 387.72, intraday low pierced at 386.35
• Middle Bollinger band at 409.47, 10-EMA at 400.17 — neither reclaimed, confirming downtrend
• RSI at 35.23, still declining; MACD histogram widening, no bullish divergence present
• 200-SMA at 344.75 — below this lies September 2025 swing low at 338.30, then August 2024 low near 256
• Aggressive analyst's 1:1 risk-reward (11% downside to 200-SMA vs. 10-11% upside to 50-SMA) anchors to best-case downside scenario
• Stop at 355 is placed at prior April gap area — structurally relevant level to limit tail risk
• Concentration trim of 25-50% reduces position to 1.5-2% of portfolio — appropriate for elevated legal, regulatory, and fundamental uncertainty
• Recovery thesis requires medical cost trend normalization, legal overhang dissipation, and EPS estimates holding — three simultaneous conditions
• Conservative case requires only avoiding one meaningful adverse event in next quarter

→ vs aggressive: Operating margin collapse from 8.7% to 4.2% cannot be attributed solely to Change Healthcare cyberattack; gross margin fell from 24.5% to 18.5% in 2025, and OCF declined 32% over two years — these reflect structural business model pressure, not one-time charges

→ vs aggressive: Forward P/E of 17.3x appears cheap only because the earnings denominator is built on optimistic assumptions; any EPS cut of 10-20% (possible from IRS audit, lawsuit discovery, or continued cost pressure) pushes the multiple to 21x or 24x

→ vs aggressive: The 44% EPS recovery to $22.44 is a Wall Street consensus forecast, not a contractual obligation; medical cost trend is the swing factor, yet the same cost pressure is cited as justification for MA membership cuts — these views are contradictory

→ vs aggressive: Technical lower Bollinger band at 387.72 is being tested as support, not confirmed as a launchpad; in a confirmed downtrend, prices ride the lower band; mean reversion requires reclaiming the middle band at 409.47 and the 10-EMA at 400.17, neither of which has occurred

→ vs aggressive: Lower band buy thesis ignores four confirming indicators (MACD histogram widening, RSI still declining, no bullish divergence, volume elevated without climax event) — buying on one indicator while four confirm the downtrend is selective reading

→ vs aggressive: The 'market has priced in all bad news' argument is demonstrably false — investors said this at $461 in July 2024 and before the 2024 drawdown from $550 to $256; legal/regulatory events produce gaps that don't get pre-priced

→ vs aggressive: The 1:1 risk-reward framing anchors downside to the 200-SMA at 344.75 holding, but in confirmed downtrends major moving averages give way; below 344.75 lies 338.30 and then 256 — the aggressive analyst is planning for the best-case scenario

→ vs aggressive: Widening the stop from 355 to 344 increases exposure to catastrophic overnight loss if UNH gaps down on IRS disclosure or lawsuit ruling — a tighter stop forces discipline and limits tail risk

→ vs aggressive: Proposing a 15% trim while acknowledging concentration risk is the worst of both worlds — it doesn't materially reduce risk but signals the position needs trimming; 25-50% trim is the calibrated response to elevated uncertainty

BUY (trim 20% at current levels, hold remaining 80% with stop at $370)

• Forward EPS central tendency is $22.44; forward P/E of 17x already discounts partial recovery probability, making valuation reasonable rather than cheap or expensive
• Lower Bollinger band at $387.72 with close at $388.61; selling at support is suboptimal; trim should be based on portfolio construction, not indicator levels
• 200-SMA at $344 remains a respected technical level where institutional buying historically shows up; dismissing it underestimates mean-reversion probability
• Recession probability at 8% on Polymarket and falling; long-term yields easing; Fed in holding pattern—all mildly supportive for defensive healthcare names like UNH
• Three legal threads create tail risk justifying smaller position sizing but do not justify directional short; position sizing of 1.5-2% of portfolio is appropriate
• UNH has 16-year dividend increase streak, 0.63 beta, and dominant market share—these defensive characteristics support valuation on forward earnings, not just trailing multiples
• Proposed stop at $370 is tighter than aggressive ($344) or conservative ($355) because post-trim position size is smaller and downside is more contained
• Aggressive re-entry zone at $360 on volume climax with higher low formation offers defined risk; reclaim of $400 on close would neutralize immediate downtrend
• Core recovery thesis depends on medical cost trend normalization; next earnings print is the fundamental re-evaluation catalyst that supersedes technical setup

→ vs aggressive: Risk-reward of roughly 1:1 from $387 is not asymmetric—11% down to 200-SMA versus 10-11% up to 50-SMA is symmetric, not contrarian; the aggressive analyst has not argued probability of upside is meaningfully higher than downside, merely noted the price level exists

→ vs aggressive: Dismissiveness toward forward earnings estimates is analytically wrong; the aggressive analyst treats $22.44 EPS as a contractual right while the correct framing is probability-weighted central tendency that already discounts partial recovery

→ vs aggressive: Buying at lower Bollinger band while RSI at 35 has not crossed into oversold, MACD histogram is still widening (not contracting), and no bullish divergence exists—four indicators confirm the downtrend while one is being tested; this is selective reading, not asymmetric setup

→ vs conservative: Framing forward EPS as 'Wall Street estimates that get revised' is technically true but misleading; stripping forward EPS from analysis of quality compounders like UNH would have told you to never buy the stock at any point in the last decade

→ vs conservative: Dismissing the 200-SMA at $344 as easily broken underestimates how much institutional buying typically shows up around that level in quality names; the aggressive analyst was correct to anchor downside to that level

→ vs conservative: A 25-50% trim is not pure risk management—it is a directional bet that the stock goes lower; trimming 50% at $387 is crystallizing losses on half the position at lower Bollinger band support with no confirmed bounce; the conservative analyst should be more cautious about advocating reactive selling